Patent · US Active

Combinations of LSD1 inhibitors for the treatment of hematological malignancies

US11013698B2 · kind B2 · utility

0Cited by

29References

18Claims

0Family size

Assignee

Oryzon Genomics S.A. · ES

Inventors

Filippo CICERI · Barcelona, ES
Serena LUNARDI · Boston, US
Tamara Maes · Castelldefels, ES
Cristina MASCARO CRUSAT · Cornellà de Llobregat, ES
Inigo TIRAPU FERNANDEZ DE LA CUESTA · Barcelona, ES

Key dates

Filing date	Mar 13, 2017
Grant date	May 25, 2021
Priority date	—
Expiry date	Mar 13, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.